background
hydroxychloroquin
recent
receiv
emerg
use
author
fda
current
prescrib
combin
azithromycin
pneumonia
studi
safeti
hydroxychloroquin
alon
combin
azithromycin
method
new
user
cohort
studi
conduct
includ
sever
advers
event
sae
rheumatoid
arthriti
patient
age
initi
hydroxychloroquin
compar
initi
sulfasalazin
follow
day
selfcontrol
case
seri
scc
conduct
establish
safeti
wider
popul
separ
sae
associ
hydroxychloroquineazithromycin
compar
hydroxychloroquineamoxicillin
studi
data
compris
sourc
claim
data
electron
medic
record
germani
japan
netherland
spain
uk
usa
propens
score
stratif
calibr
use
neg
control
outcom
use
address
confound
cox
model
fit
estim
calibr
hazard
ratio
calhr
accord
drug
use
estim
pool
overal
user
hydroxychloroquin
sulfasalazin
user
hydroxychloroquineazithromycin
hydroxychloroquineamoxicillin
includ
excess
risk
sae
identifi
hydroxychloroquin
sulfasalazin
use
compar
scc
confirm
find
howev
azithromycin
ad
hydroxychloroquin
observ
increas
risk
cardiovascular
mortal
chest
painangina
calhr
ci
heart
failur
calhr
ci
sever
acut
respiratori
syndrom
coronaviru
pandem
exert
unpreced
pressur
health
care
system
worldwid
remain
pauciti
evid
surround
safeti
effect
potenti
treatment
sever
exist
drug
postul
effect
includ
convent
synthet
diseas
modifi
antirheumat
drug
csdmard
commonli
use
first
line
treatment
autoimmun
diseas
rheumatoid
arthriti
ra
systemat
lupu
erythematosu
sle
hydroxychloroquin
hcq
propos
potenti
treatment
option
base
mechan
action
accumul
acid
vesicl
endosom
golgi
vesicl
lysosom
hcq
caus
alkalinis
lead
enzym
dysfunct
prevent
endosom
mediat
viral
entri
cell
also
suggest
vitro
hcq
prevent
glycosyl
viru
cell
protein
includ
receptor
inhibit
viru
entri
replic
similar
compound
like
chloroquin
specif
inhibit
clinic
studi
addit
hcq
shown
increas
earli
virolog
respons
treatment
chronic
hepat
c
reduc
viral
load
patient
hiv
infect
compar
placebo
treatment
hcq
also
lower
level
hiv
patient
suggest
agent
may
immunosuppress
properti
help
prevent
treatment
cytokin
storm
associ
sever
diseas
th
march
regist
ongo
clinic
trial
prophylact
studi
assess
efficaci
hydroxychloroquin
hcq
treatment
earli
result
randomis
control
trial
conduct
china
shown
reduc
sever
cours
diseas
hydroxychloroquin
hcq
compar
placebo
without
detect
seriou
advers
effect
although
other
suggest
differ
outcom
convent
treatment
studi
report
detail
result
receiv
signific
media
attent
hcq
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
propos
higher
dose
use
treatment
autoimmun
disord
alongsid
azithromycin
azm
macrolid
antibiot
result
open
label
observ
studi
suggest
combin
hcq
azithromycin
azm
might
lead
faster
recoveri
reduct
viral
load
treatment
howev
mani
author
criticis
studi
due
lack
low
power
limit
followup
confound
indic
lack
adher
alloc
treatment
arm
efficaci
hcq
combin
azm
therefor
yet
establish
approv
compassion
use
regul
media
attent
like
lead
increas
use
combin
therapi
manag
worldwid
prepar
studi
systemat
search
literatur
pubm
embas
clinic
trial
registri
clinicaltrialsgov
ictrp
chines
clinic
trial
registri
preprint
server
biorxiv
medrxiv
incept
supplementari
appendix
section
contemporari
largescal
evid
found
identifi
realworld
compar
safeti
hcq
compar
first
line
dmard
especi
combin
macrolid
antibiot
azm
consid
use
treat
sepriano
et
al
led
systemat
review
inform
eular
recommend
safeti
ra
medic
littl
highlevel
evid
focuss
hcq
anoth
recent
review
compar
risk
nonseri
seriou
advers
event
sae
associ
dmard
predominantli
focuss
upon
biolog
therapi
littl
good
high
qualiti
evid
quantifi
sae
risk
literatur
sever
studi
suggest
increas
infect
risk
nonbiolog
dmard
includ
hcq
safeti
profil
hcq
describ
summari
product
characterist
advers
drug
reaction
includ
sever
cardiac
disord
qt
segment
prolong
could
lead
arrhythmia
myocardi
arrest
cardiovascular
death
azithromycin
azm
macrolid
gener
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
known
induc
cardiotox
use
alon
also
increas
risk
drug
prolong
qtc
interv
therefor
utmost
import
understand
safeti
implic
propos
combin
hcq
azithromycin
azm
becom
standard
practic
manag
global
light
current
global
pandem
inform
regard
safeti
hcq
worldwid
realworld
practic
vital
inform
polici
aim
assess
safeti
hydroxychloroquin
hcq
alon
combin
azm
help
guid
decis
face
grow
pandem
two
studi
design
develop
execut
across
multin
distribut
databas
network
first
new
user
cohort
studi
use
estim
safeti
hcq
compar
sulfasalazin
ssz
assess
risk
associ
addit
azm
compar
amoxicillin
amx
amongst
user
hcq
patient
rheumatoid
arthriti
ra
ssz
amx
chosen
activ
compar
similar
indic
target
treatment
hcq
azm
respect
secondari
analysi
selfcontrol
case
seri
scc
use
estim
safeti
hcq
wider
popul
includ
use
nonra
indic
electron
health
record
administr
claim
databas
primari
care
secondari
care
contain
particip
germani
japan
netherland
spain
uk
usa
analys
distribut
network
detail
supplementari
appendix
tabl
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
observ
healthcar
databas
map
observ
medic
outcom
partnership
omop
common
data
model
collabor
intern
effort
observ
health
data
scienc
informat
ohdsi
commun
deidentifi
pseudonymis
data
obtain
routin
collect
record
clinic
practic
germani
spain
uk
japan
usa
studi
perform
local
patient
level
data
share
use
follow
databas
iqvia
diseas
analys
germani
emr
ambulatori
emr
germani
jmdc
japanes
claim
ipci
primari
care
emr
netherland
sidiap
primari
care
emr
spain
cprd
imdr
primari
care
emr
uk
ccae
optum
mdcr
mdcd
panther
iqvia
openclaim
veteran
affair
va
iqvia
us
ambulatori
emr
usa
scc
conduct
subset
secondari
analysi
ccae
cprd
optum
mdcd
mdcr
rather
pool
data
asset
analys
conduct
distribut
network
analysi
code
sent
particip
site
aggreg
summari
statist
return
share
patientlevel
data
organ
studi
period
start
end
latest
avail
date
data
sourc
followup
cohort
start
index
date
defin
first
dispens
prescript
targetcompar
drug
describ
cohort
definit
supplementari
tabl
two
period
consid
defin
timeatrisk
first
intentiontotreat
analysi
followup
start
one
day
index
date
continu
first
outcom
interest
loss
followup
day
index
date
resembl
like
durat
treatment
regimen
secondli
ontreat
analysi
followup
start
one
day
index
date
continu
earliest
outcom
interest
loss
followup
discontinu
ad
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
washout
time
day
continu
use
treatment
infer
allow
gap
dispens
prescript
record
hcq
versu
ssz
studi
index
event
defin
first
record
dispens
prescript
drug
patient
histori
studi
hcq
combin
azm
follow
start
second
two
coadminist
treatment
initi
still
expos
first
treatment
eg
azm
start
period
hcq
use
hcq
start
period
azm
use
hcq
use
assum
chronic
manag
ra
azm
assum
acut
prescript
infect
treatment
therefor
infer
persist
exposur
azm
assess
allow
day
dispens
prescript
record
cohort
combin
hcq
amoxicillin
gener
use
rule
activ
compar
ssc
period
infer
persist
exposur
hcq
gener
allow
gap
dispens
prescript
record
individu
scc
analys
execut
separ
propos
studi
outcom
includ
safeti
event
neg
control
outcom
patient
follow
entir
observ
time
eg
enrol
disenrol
databas
incid
rate
studi
outcom
calcul
period
infer
persist
exposur
hcq
nonexposur
period
new
user
cohort
particip
includ
histori
ra
condit
occurr
observ
indic
ra
time
day
therapi
initi
age
year
index
event
least
day
continu
observ
time
prior
index
event
inclus
start
followup
start
time
one
drug
interest
hcq
ssz
addit
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
azm
amx
amongst
user
hcq
initi
diagnosi
ra
scc
studi
preval
user
hcq
includ
regardless
ra
histori
indic
hcq
therapi
particip
identifi
use
prespecifi
code
list
review
core
team
clinician
epidemiologist
vocabulari
expert
health
data
scientist
extens
expertis
use
omop
cdm
ohdsi
tool
code
list
omop
cdm
use
identifi
particip
list
supplementari
tabl
propos
code
list
identif
studi
popul
studi
exposur
creat
clinician
experi
manag
ra
use
atla
review
clinician
epidemiologist
supplementari
tabl
total
sever
advers
event
sae
analys
hospitalbas
event
avail
primari
care
record
cprd
imrd
sidiap
includ
gastrointestin
bleed
acut
renal
failur
acut
pancreat
myocardi
infarct
stroke
transient
ischaem
attack
cardiovascular
event
composit
addit
anginachest
pain
heart
failur
cardiac
arrhythmia
bradycardia
venou
thromboembol
end
stage
renal
diseas
hepat
failur
analys
primari
secondari
care
data
mortal
outcom
obtain
data
sourc
reliabl
inform
death
date
cprd
imrd
ipci
optum
sidiap
va
cardiovascular
event
preced
death
record
cprd
imrd
optum
va
former
contribut
inform
allcaus
mortal
latter
also
use
assess
cardiovascular
death
code
identif
propos
studi
outcom
base
previous
publish
paper
detail
supplementari
tabl
face
valid
outcom
cohort
review
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
explor
ageand
sexspecif
incid
rate
compar
previou
clinic
knowledg
andor
exist
literatur
two
activ
compar
analys
conduct
cohort
studi
first
incid
user
hcq
compar
new
user
ssz
second
new
use
azm
amongst
preval
user
hcq
compar
incid
use
amx
ongo
hcq
use
exposur
commenc
first
day
dispens
prescript
record
least
day
prior
observ
period
increas
confid
exposur
incid
exposur
interv
gap
day
hcq
ssz
day
azm
amx
drug
dispens
prescript
record
allow
infer
persist
exposur
drug
discontinu
consid
hcq
studi
patient
switch
one
studi
drug
anoth
patient
switch
target
exposur
compar
exposur
vice
versa
contribut
followup
time
exposur
cohort
enter
first
censor
time
switch
treatment
analysi
list
neg
control
outcom
also
assess
known
causal
relationship
drug
interest
outcom
identifi
use
semiautomat
process
base
data
extract
literatur
product
label
spontan
report
confirm
manual
review
clinician
full
list
code
use
identifi
neg
control
outcom
found
supplementari
tabl
detail
covariateconfound
identif
provid
supplementari
tabl
studi
undertaken
use
routin
collect
data
patient
meet
elig
criteria
studi
observ
period
includ
priori
sampl
calcul
perform
instead
minimum
detect
rate
ratio
mdrr
estim
drugoutcom
pair
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
avail
databas
mdrr
databas
drug
pairoutcom
analysi
well
sampl
size
comparison
report
full
interact
web
app
http
analys
count
either
treatment
group
exclud
base
power
other
contribut
metaanalyt
estim
applic
ps
stratif
use
analyt
strategi
adjust
imbal
exposur
cohort
comparison
use
largescal
regular
logist
regress
fit
lasso
penalti
optim
hyperparamet
determin
cross
valid
baselin
patient
characterist
construct
inclus
potenti
confound
covari
larg
set
ten
thousand
covari
key
predictor
exposur
classif
select
propens
score
predictor
variabl
includ
base
observ
patient
characterist
covari
avail
data
sourc
includ
condit
procedur
visit
observ
measur
covari
occur
fewer
patient
within
target
compar
cohort
exclud
prior
propens
score
model
fit
comput
effici
patient
target
compar
cohort
stratifi
propens
score
quintil
plot
propens
score
distribut
assess
covari
balanc
express
standard
differ
mean
undertaken
everi
covari
propens
score
adjust
standard
differ
indic
nonneglig
imbal
exposur
cohort
target
compar
cohort
compar
use
univari
cox
proport
hazard
model
condit
propens
score
strata
treatment
alloc
sole
explanatori
variabl
neg
control
outcom
analys
empir
calibr
use
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
minimis
potenti
unresolv
confound
calibr
hr
calhr
confid
interv
estim
scc
safeti
hcq
therapi
assess
separ
secondari
analysi
regardless
indic
compar
expos
unexpos
time
period
within
individu
method
selfcontrol
make
withinperson
comparison
event
rate
period
hypothes
increas
risk
period
baselin
risk
elimin
timeinvari
confound
compar
person
scc
robust
betweenperson
differ
even
includ
unmeasur
differ
like
genet
howev
method
vulner
timevari
confound
time
exposur
may
incompar
time
expos
adjust
includ
mani
timevari
covari
model
includ
age
season
drug
exposur
effect
age
season
assum
constant
within
calendar
month
model
use
bicub
spline
knot
condit
poisson
regress
use
fit
outcom
model
use
cyclop
packag
hyperparamet
select
crossvalid
studi
diagnost
power
propens
score
distribut
covari
balanc
empir
null
distribut
evalu
clinician
epidemiologist
determin
databasetargetcomparatoroutcomeanalysi
variant
could
produc
unbias
estim
databasetargetcomparatoranalysi
variant
zero
event
outcom
timeatrisk
window
contain
analys
baselin
covari
standard
mean
differ
stratif
exclud
analysi
studi
diagnost
databasetargetcomparatoroutcomeanalysi
provid
part
studi
regardless
effect
estim
result
unblind
propos
analys
conduct
databas
separ
estim
combin
fix
effect
metaanalysi
method
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
metaanalysi
conduct
given
drugoutcom
pair
note
run
analysi
distribut
network
possibl
link
across
dataset
know
extent
overlap
data
analyt
code
avail
http
studi
diagnost
consid
prior
unblind
estim
result
studi
diagnost
avail
explor
http
statist
analys
conduct
use
tool
previous
valid
ohdsi
commun
cohort
analysi
cohortmethod
packag
use
http
ohdsigithubiocohortmethod
use
largescal
propens
score
ps
construct
cyclop
packag
http
ohdsigithubiocyclop
scc
run
use
freeli
avail
packag
http
ohdsigithubioselfcontrolledcaseseri
total
hcq
ssz
user
identifi
contribut
analys
combin
therapi
hcq
azm
compar
hcq
amx
respect
particip
count
data
sourc
provid
appendix
user
hcq
like
femal
eg
vs
ccae
less
like
certain
comorbid
like
inflammatori
bowel
diseas
eg
preval
crohn
diseas
vs
ccae
psoriasi
eg
vs
ccae
differ
howev
minimis
propens
score
stratif
report
analys
balanc
identifi
confound
includ
sociodemograph
comorbid
concomit
drug
use
similarli
user
combin
hcqazm
differ
hcqamx
preval
acut
respiratori
diseas
appear
higher
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
amongst
azithromycin
user
vs
ccae
propens
score
method
resolv
differ
comparison
group
becam
balanc
observ
confound
stratif
detail
baselin
characterist
hcq
vs
ssz
hcqazm
vs
hcqamx
propens
score
stratif
ccae
detail
tabl
report
tabl
databasespecif
count
rate
key
outcom
cardiovascular
mortal
chest
painangina
heart
failur
observ
propos
intentiontotreat
analysi
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
databasespecif
count
incid
rate
ir
studi
outcom
stratifi
drug
use
detail
full
supplementari
tabl
least
common
outcom
includ
bradycardia
eg
ir
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
personyear
py
amongst
hcq
user
ccae
endstag
renal
diseas
eg
ir
py
amongst
hcq
user
ccae
whilst
common
one
chest
painangina
eg
ir
py
amongst
hcq
user
ccae
composit
cardiovascular
event
eg
ir
py
amongst
hcq
user
ccae
expect
ir
appear
higher
data
sourc
includ
older
popul
eg
ir
composit
cardiovascular
event
hcq
user
mdcr
py
mortal
rate
rang
personyear
hcq
user
optum
py
amongst
hcq
user
va
cardiovascularspecif
mortal
rang
ir
py
hcq
user
va
personyear
ssz
user
data
sourc
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
figur
metaanalyt
risk
estim
hydroxychloroquin
vs
sulfasalazin
azithromycin
vs
amoxicillin
new
user
ontreat
ontreat
followup
hcqhydroxychloroquin
sszsulfasalazin
azmazithromycin
plu
concurr
hydroxychloroquin
exposur
amxamoxicillin
plu
concurr
hydroxychloroquin
exposur
calhrcalibr
hazard
ratio
ciconfid
interv
heterogen
statist
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
consist
find
seen
longterm
treatment
use
hcq
vs
ssz
figur
except
cardiovascular
mortal
appear
inconsist
avail
databas
overal
increas
hcq
group
metaanalys
pool
calhr
similar
result
obtain
scc
analys
look
effect
hcq
use
onv
offtreat
outcom
except
mortal
regardless
indic
therefor
includ
nonra
patient
tabl
databasespecif
result
obtain
databaseand
outcomespecif
calhr
associ
shortterm
month
use
hcqazm
vs
hcqamx
depict
form
forest
plot
supplementari
figur
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
figur
despit
lack
evid
efficaci
hcq
hcqazm
becom
popular
treatment
largest
ever
analysi
safeti
treatment
worldwid
examin
hcq
hcqazm
user
respect
result
risk
sae
associ
shortterm
month
hcq
treatment
propos
therapi
reassur
excess
risk
consid
safeti
outcom
compar
equival
therapi
ssz
howev
longterm
treatment
hcq
use
ra
associ
increas
cardiovascular
mortal
worryingli
signific
risk
identifi
combin
user
hcqazm
even
shortterm
propos
manag
increas
risk
anginachest
pain
heart
failur
twofold
risk
cardiovascular
mortal
first
month
treatment
systemat
review
cardiac
side
effect
chloroquin
hcq
identifi
articl
report
short
seri
individu
case
includ
patient
cardiac
side
effect
occur
mainli
women
median
age
year
conduct
disord
main
side
effect
report
heart
failur
ventricular
hypertrophi
hypokinesia
valvular
dysfunct
pulmonari
arteri
hypertens
report
side
effect
drug
withdrawn
patient
recov
normal
cardiac
function
sustain
irrevers
damag
die
note
cardiac
toxic
induc
high
cumul
dose
chloroquin
hcq
patient
although
studi
identifi
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
result
suggest
longterm
use
hcq
lead
increas
risk
cardiovascular
mortal
observ
excess
risk
major
cardiovascular
event
diagnos
bradycardia
consid
current
evid
may
relat
cumul
effect
hcq
lead
increas
risk
qt
lengthen
relat
moder
increas
risk
angina
heart
failur
seen
howev
strong
associ
observ
cardiovascular
death
observ
diagnos
arrhythmia
bradycardia
studi
sudden
cardiovascular
death
like
due
qt
lengthen
undetect
andor
sudden
torsadedepoint
although
longterm
treatment
hcq
expect
manag
research
suggest
higher
dose
prescrib
even
shortterm
lead
equival
side
effect
given
long
halflif
hcq
qt
lengthen
known
effect
macrolid
includ
azm
physician
alreadi
use
caution
prescrib
macrolid
concurr
medic
also
increas
qt
interv
studi
elev
risk
cardiovascular
death
combin
hcq
azm
therapi
may
aris
synergist
effect
induc
lethal
arrhythmia
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
observ
data
studi
limit
abil
appropri
identifi
exposur
outcom
due
natur
sudden
cardiac
death
captur
true
caus
cardiovascular
relat
mortal
difficult
therefor
explor
cardiovascular
relat
outcom
mortal
determin
deterior
pathophysiolog
process
led
increas
mortal
sinc
seen
sudden
cardiac
death
associ
prolong
qt
interv
describ
literatur
conclus
drawn
assumpt
acknowledg
misclassif
occur
due
nonadher
noncompli
exposur
medic
incomplet
lack
record
sae
may
lead
underestim
outcom
anoth
potenti
limit
studi
potenti
patient
includ
one
dataset
us
whilst
ran
metaanalysi
assum
popul
independ
wish
highlight
like
underestim
varianc
metaanalyt
estim
compar
new
user
cohort
studi
anchor
patient
use
hcq
ra
therefor
like
use
hcq
lower
dose
current
propos
use
treatment
taken
consider
patient
ra
take
hcq
may
also
autoimmun
condit
system
lupu
erythematosu
sle
therefor
gener
potenti
confound
indic
therefor
ensur
investig
covari
balanc
propens
score
stratif
match
unblind
studi
result
see
unbalanc
proport
patient
diagnosi
sle
group
neg
control
outcom
analys
also
identifi
residu
unobserv
confound
ps
analysi
whilst
patient
ra
may
greater
level
comorbid
gener
popul
age
demograph
profil
patient
develop
cardiovascular
complic
describ
systemat
review
faer
databas
suggest
complic
restrict
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
multimorbid
howev
absolut
risk
studi
interpret
cautious
sinc
patient
ra
like
differ
world
await
result
clinic
trial
antivir
efficaci
hcq
treatment
infect
larg
scale
intern
realworld
data
network
studi
enabl
us
consid
safeti
popular
drug
consider
hcq
appear
larg
safe
direct
compar
analysi
short
term
use
use
combin
azm
therapi
carri
doubl
risk
cardiovascular
death
patient
ra
wherea
use
collect
experi
million
patient
build
confid
evid
around
safeti
profil
current
evid
around
efficaci
hcqazi
treatment
quit
limit
controversi
data
partner
receiv
irb
approv
waiver
accord
institut
govern
guidelin
retrospect
databas
studi
deidentifi
data
deem
human
subject
research
approv
provid
ohdsi
commun
studi
ccae
new
england
institut
review
board
irb
determin
exempt
broad
irb
approv
research
project
involv
human
subject
research
cprd
approv
cprd
provid
independ
scientif
advisori
committe
isac
studi
base
part
data
full
featur
gener
practic
research
databas
obtain
licens
uk
medicin
healthcar
product
regulatori
agenc
howev
interpret
conclus
contain
report
author
alon
protocol
studi
approv
independ
scientif
advisori
committe
isac
ccbync
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
da
germani
retrospect
databas
studi
deidentifi
data
deem
human
subject
research
approv
provid
ohdsi
commun
studi
present
studi
file
review
scientif
review
committe
institut
adjud
due
public
health
imper
inform
relat
data
approv
provid
public
ipci
present
studi
approv
scientif
ethic
advisori
board
ipci
project
project
number
jmdc
new
england
institut
review
board
irb
determin
exempt
broad
irb
approv
research
project
involv
human
subject
research
mdcd
new
england
institut
review
board
irb
determin
exempt
broad
irb
approv
research
project
involv
human
subject
research
mdcd
new
england
institut
review
board
irb
determin
exempt
broad
irb
approv
research
project
involv
human
subject
research
open
claim
retrospect
databas
studi
deidentifi
data
deem
human
subject
research
approv
provid
ohdsi
commun
studi
optum
new
england
institut
review
board
irb
determin
exempt
broad
irb
approv
research
project
involv
human
subject
research
panther
new
england
institut
review
board
irb
determin
exempt
broad
irb
approv
research
project
involv
human
subject
research
use
sidiap
data
base
approv
sidiap
scientif
committe
idiapjgol
clinic
research
ethic
committe
va
use
va
data
review
depart
veteran
affair
central
institut
review
board
irb
determin
meet
criteria
exempt
exempt
categori
approv
request
waiver
hipaa
author
va
privaci
offic
certifi
releas
aggreg
analysi
result
metaanalysi
author
complet
icmj
uniform
disclosur
form
wwwicmjeorgcoidisclosurepdf
authorfund
grant
medrxiv
licens
display
preprint
perpetu
peerreview
copyright
holder
preprint
http
doi
medrxiv
preprint
tremend
work
dedic
particip
nation
march
ohdsi
virtual
studyathon
http
without
studi
could
realiz
